Profitelligence Profitelligence · Filing Ledger Open ZTS research →

Form 8-K · Current Report · Filed 2024-10-10

Zoetis Inc. Declares Fourth Quarter 2024 Dividend

Zoetis Inc. announced on October 10, 2024, that its Board of Directors declared a dividend of $0.432 per share for the fourth quarter of 2024, payable on December 3, 2024, to shareholders of record as of October 31, 2024. This announcement was made in conjunction with the filing of the Form 8-K under Regulation FD, and the dividend details were further disclosed in an attached press release.

Filer
Zoetis Inc. ZTS · NYSE
Filed
Accession
0001555280-24-000326
CIK
0001555280
Signal
Medium impactHealthcare

Items reported

Item 7.01

Regulation FD Disclosure

Dividend Announced
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$190.17

Next session

-0.0%

Since filing

-59.4%

Latest close

$77.29

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from ZTS reporting the same item, with the next session's move:

Exhibits (1)

About Zoetis Inc.

Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.

Exchange NYSE Industry Drug Manufacturers - Specialty & Generic Company website ↗

Never miss another ZTS filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts